forward looking statements · the following slides may contain certain summary information about...

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 1 -

Dr. Thomas Schweins

Vice President Marketing and Strategy

Morgan Stanley Global Healthcare Unplugged Conference

Miami, May 04, 2006


Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

The following slides may contain certain summary information about QIAGEN N.V.’s operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures”basis rather than in accordance with U.S. generally accepted accounting principles (“GAAP”). Please review QIAGEN’s recent press releases for information on the company’s operating income, net income, and earnings per share for specific periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F and 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission and which are available on QIAGEN’s homepage under www.QIAGEN.com.

Forward Looking Statements


Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

Technology Leadership



Pre-Analytical Sample PreparationIsolation Of Target Analyte From Complex Biological Samples

Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors,

Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils,

Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins,

Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins,

Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli,

Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides,

Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes,

Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes,

Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum

albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma

membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, DNA, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus,

Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin,

mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth

endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting

factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts,

Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin,

Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria,

Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars,

Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages,

Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum,

Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles,

Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, , …

Complexsample

Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors,

Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils,

Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins,

Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins,

Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli,

Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides,

Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes,

Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes,

Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum

albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma

membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, DNA, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus,

Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin,

mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth

endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting

factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts,

Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin,

Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria,

Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars,

Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages,

Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum,

Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles,

Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, , …

High-TechDevice

DNAPure

Analyte



QIAGEN: Sample And Assay Technologies

QIAGEN: The Leader in pre-analytical tools and assays

Unparalleled range of applications

Standardizes processes

Time savings

Highest purity

Automation

Up-scaling

Non- toxic reagents used

Highest convenience

Ease of use

Compatible with down-stream applications

Easiest integration into already existing platforms

Addressing more than different 100 applicationsAddressing more than different 100 applications



QIAGEN Product DimensionsAny Sample – Any Analyte – Any Assay

Different Forms ofNucleic Acids/Genetic Information

Assays/Applications

Biologicalsamples



Combining Chemistry, Biology and EngineeringQIAGEN Technology and Innovation Leader

QIAGEN Technologies

Chromatography, Selective adsorption,

Filtration, Magnetic bead, Thin membrane,

Hybrid capture, Endotoxin removal, PCR

Transfection, Whole genome amplification,

etc., etc., etc.

Engineering - Automation

Hardware design perfection

Software development platforms

Electronic engineering

Comprehensive Intellectual Property Estate

Over 400 patents

Over 320 pending applications

Over 500 patents under license

Chemistry

Engineering

Application knowledge

Ergonomics Biology

Robotics



Automation Harvests Consumable StreamQIAGEN’s Automation Strategy Technology

Leadership

1 6 48 96 samples (manual)

Approx 85%

of Sales

BioSprintEZ1

$28,000

BR M48 - M96BR 3000

$40,000-80,000

BR 8000 and UHT systems$70,000 and up

1 6 48 96 (>20,000) samples (autom)

Approx 15%

of Sales


Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

Technology Leadership Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

QIAGEN has SignificantMarketing and Sales Power Sales strength


Strong Sales and Marketing Force (Q4 2005)

Americas < 50% of Sales: Sales and Marketing Force: 243

Europe Approx 40% of SalesSales and Marketing Force: 329

Asia Approx 10% of SalesSales and Marketing Force: 84

673 sales and marketing professionals – on one clear and focused mission

673 sales and marketing professionals – on one clear and focused mission

MARKETS

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

SPECIALISTS

Channels

Sales strength


Academia (approx. 40% of revenues)

Europe strong (esp. Germany), US strong finish

Japan still underperforms, but improving

Pharma/Biotech (approx. 25% of revenues)

Stronger in US, softer in EU

QIAGEN strategic partner in all stages of drug

development

Expanded targeted pharma resources

Applied testing (approx. 10% of revenues)

Accelerating growth rates

QIAGEN initiatives make an impact

Diagnostics (approx. 25% of revenues)

Building substantial presence

Today one of the largest MDx companies WW

QIAGEN – Focusing on key areas for growth

Markets by CustomerSales strength


Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

Financials


QIAGEN is Addressing Key Growth MarketsGrowth Drivers

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001


QIAGEN With Strong Growth ContinuityOrganic Growth Rate: Quarterly Growth Q1-04 until Q4-05

(1) Incl. Competitor: Beckman, Bruker, Strategyn, BioRad, Mettler, ABI, Affymetrix, Fisher, Walers, Thermo, Techne, Invitrogen, Sigma, QIAGEN, Millipore, Roche Applied Science, Tecan

Source: Company data, Analyst reports

QuarterlyGrowth

IndustryAverage(1)

QIAGEN

Q1 04 Q3 04 Q4 04 Q1 05Q2 04 Q2 05 Q3 05 Q4 05

QIAGENQIAGEN

AverageAverage

Growth Drivers


3 Major Growth Driver Accelerate QIAGEN’s Performance

3

1

2

Innovation

New market segments• Molecular Diagnostics• Applied Testing

Geographical Expansion


Significant Growth in Molecular DiagnosticMarkets Addressable by QIAGEN

0.0

5.0

10.0

15.0

20.0

25.0

1995 2000 2005 2010 2015

Life Sciences Molecular Diagnostics Applied Testing

CAGRs 2005-2015

Life Sciences: 4-6%

Molecular. Dx: ~20%

Appl. Testing: >20%

QIAGEN is targeting key growth marketsQIAGEN is targeting key growth markets

1

Segments


Our Portfolio of Markets – 7 year Outlook

Relative Position (Market Share)

Business Growth Rate

Academia/Pharma/BiotechResearch

MolecularDiagnostics

AppliedTesting

1

Segments


Molecular Diagnostics at QIAGENA Complete Portfolio for all Relevant Infectious Diseases

• CMV LC CE

• CMV RG CE

• CMV TM CE

• HSV 1/2 RG CE

• HSV 1/2 TM Abbott

• C. trachomatis TM CE

• C. trachmoatis RG CE

• C. trachomatis LC CE

• M. pneumoniae LC CE

• B. pertussis LC CE

• Enterovirus LC

• L. pneumophila LC

• SARS Coronavirus LC CE

• SARS Coronavirus RG CE

• SARS Coronavirus TM CE

• B. anthracis LC

• B. anthracis RG

• B. anthracis TM

• HAV LC CE

• HAV RG CE

• HAV TM CE

• WNV TM

• B. pertussis RG CE

• C. trachomatis Plus TM CE

• C. trachomatis Plus LC CE

• C. trachomatis Plus RG CE

• HIV-1 RG CE

• VZV RG CE

• Salmonella LC

• Salmonella RG

• Salmonella TM

• Campylobacter LC

• Campylobacter RG

• Campylobacter TM

• Dengue RG

• Influenza/H5 LC

• M. tuberculosis LC CE

• M. tuberculosis RG CE

• M. tuberculosis TM CE

• Malaria diff QC LC

• M. paratuberculosis LC CE

• Mycobac. diff LC CE

• Hemochromatosis LC CE

• Factor II/V LC CE

• HBV LC CE

• HBV RG CE

• HBV TM CE

• EBV LC CE

• EBV RG CE

• EBV TM CE

• Borrelia LC CE

• Influenza LC

• Orthopox LC

Representative but not complete list

1

Molec. Diagnostic


“Panel” Approach

Transplantation Panel:

Viral: CMV, EBV, HSV-1/2, VZV, HHV-6

Fungal: Candida, Aspergillus

Respiratory Panel (upper and lower)

Viral: Influenza, RSV, Metapneumovirus, Adenovirus, SARS

Bacterial: Bordetella, M. pneumoniae, C. pneumoniae,

L. pneumophila, M. tuberculosis

Encephalitis Panel

Viral: HSV-1/2, Enterovirus, West Nile virus, Adenovirus, Parvo B19, Influenza, CMV, EBV

Bacterial: Borrelia, M. pneumoniae, M. tuberculosis

Gastro-intestinal Panel:

Viral: Norwalk-(Norovirus), Rota-, Astrovirus

Bacterial: Campylobacter, Salmonella

Blood Panel

Viral: Parvo B19, HIV, HAV, HBV, (HCV)

1

Molec. Diagnostic


QIAGEN – a Leader in Molecular Diagnostics

Estimated market:

> US$ 2 billion (2006)

USD Sales inMolecular

Company Diagnostics

Roche 550Genprobe 300Bayer 120QIAGEN 115Digene 115Abbott 110Others

CepheidBiomerieuxBecton DickinsonCelera DxBeckmanInnogeneticsVeridexNanogenThird WaveExactetc.

QIAGEN is a leading player in molecular diagnosticsQIAGEN is a leading player in molecular diagnosticsSource: company estimates, various industry research reports

Viral Infections39%

Non-Viral Infections12%

Genetic Testing13%

Oncology11%

Blood banksOthers25%

!

1

Molec. Diagnostic


Applied Testing – A Field Of Opportunities 1

Applied Testing


VeterinaryDX

HumanIdentity

FoodGMO

FoodPathogens

BiosecurityPGx

Pharma& PCP

QC

Different Segments At Different StagesApplied Testing Market Segments

Applied Testing:

Early markets

Emerging applications

Diverse segments

Regional differences

High growth

Conversion from traditional methods

Use of molecular testing varies

QIAGEN: World Leading in areas such as Avian Flu animal testing or forensicsQIAGEN: World Leading in areas such as Avian Flu animal testing or forensics

1

Applied Testing


Molecular Testing Reality Even For Unexpected Applications

Food allergy testing

Genotyping of race horses - the UK studbook

Identification of victims from mass disasters such as 9/11, Katrina, Tsunami

Quality monitoring of water supplies for viruses

Mozart‘s (?) skull

Detection of salmonella in food

Rugby in Australia – competitive edge through genetically tailored training

Forensics – O.J. Simpson, Mooshammer, Dutroux

Genotyping of wine barrels to ensure correct origin of oak wood

Nutrigenomics – a diet plan depending on your metabolizing profile

Crocodile forensics – tracking of crocodile products in the market

Avian flu – surveillance testing of birds to prevent the spread of the disease

Food identity testing – is it really Angus?

Applied Testing Today

QIAGEN is the leader in Applied TestingQIAGEN is the leader in Applied Testing

1

Applied Testing


Automation

Regulation Highly Demanding Sample Prep

Standardization

Demanding Needs, Similarities To Human MDXNeeds In Applied Testing Markets

CollectionStabilization

SamplePreparation

PCR-Assay

Detection

1

Applied Testing


Demanding Needs, Similarities To Human MDXNeeds In Applied Testing Markets

1

Applied Testing

Integrated solutions from sample collection to analysis

Automation

Regulation Highly Demanding Sample Prep

Standardization

Automation is a prerequisite, due to low training of staff

Flexible throughput, e.g. outbreaks

Need for low- to high-throughput platforms

Most segments regulated

Different regulatory authorities per segment

Complex & diverse materials

Large sample amounts

Low copy number of analytes


Focus 2006: Accellerated Expansion in AsiaQIAGEN Worldwide

QIAGEN China Representative OfficeChina Tiangen Biotech (Beijing)

PGBiotech Co., Ltd.

Australia QIAGEN Pty Ltd

Canada QIAGEN Inc.Nextal Biotechnologies

France QIAGEN S.A.

Germany QIAGEN GmbHQIAGEN Hamburg GmbH

Italy QIAGEN S.p.A.

Japan QIAGEN K.K.

Switzerland QIAGEN AGQIAGEN Instruments AG

UK QIAGEN Ltd.

USA QIAGEN North American HoldingsQIAGEN Inc.QIAGEN Sciences Inc.

Norway QIAGEN AS

Distributors

Netherlands QIAGEN N.V.QIAGEN Benelux B.V.

Austria QIAGEN Vertriebs GmbH

Sweden QIAGEN AB

Malaysia QIAGEN Sdn. Bhd.

2Geographical

Expansion

Significant room for growth in Asia, South America, Eastern EuropeSignificant room for growth in Asia, South America, Eastern Europe


Develop: Innovation Driving Growth

Industry average

QIAGENaverage

QIAGEN2005

Time

NewProducts

RatioInnovation

processes changed in 2004

QIAGEN = Innovation Leader QIAGEN = Innovation Leader

3

Innovation


Develop: 2005 Was A Very Innovative YearSuccessfully Launched Over 50 New Products

FlexiblesiRNA Design

Protein BioSprint 15

Qproteome

CE PAXgene

GlobinReduction Kit

HiPerFect

Genome-wide siRNA

Validated siRNA

PAXgeneautomation

BR Universal

QT Rev Transcription

QuantiTectAssays

Fastlane

gDNA plantBiosprint

REPLI-g

Plasmid Facelift

Compact Prep

Large ScalePlasmid

AllPrep

RNeasy Plus

DruggableGenome

HotStar Taq Plus

QuantiTectMultiplex 1-Step

RT-PCR

Artus BirdfluAssay

PG BirdfluAssay

LiquiChipApoptosis

EasyExpress

EZ1 DNA 'Forensics' Kit

HotStar Hifidelity

3

Innovation

The „Class of 2005“ was a great success.The „Class of 2005“ was a great success.

Dissemination

Standardization& Integration

SystemsBiology


Partnering Strategy Enhances Innovation ProgramImplementing the Strategy

Partnering: Integral part of QIAGEN’s strategyPartnering: Integral part of QIAGEN’s strategy

Dissemination


SystemsBiology


Catalytic Acquisition Accelerate Internal InnovationImplementing the Strategy

„QIAGEN…was one of the mostacquisitive companies in the industry this year!

GenomeWeb

„We are impressed by their targetedacquisitions. Morgan Stanley

„Smart deals – great fit!“Deutsche Bank

Dissemination


SystemsBiology


Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001


Financials

Financials


Fiscal 2005 Financials

and

Guidance 2006

Financials


405-407 net sales

(guided Nov. 8, 2005)

0.44-0.47 EPS*

Operating margin: 24-26%

Target Achieved

Strategic Targets

2

Financial Targets

1

Other Targets

3

Reached 409 FX guidance rate

Reached 0.45 cents EPS*

Operating margin: 26%

Increasing market leadership

vs. homebrew & competition

Increasing tech leadership

Rapidly grow MDX business

Done

Significant expansion

Grew into #4 in market (!)

Prove innovation success

Execute strategy

Build channels

3x incr. new product revs (!)

Internal targets delivered

Done, continues

Meeting Targets

Difficult year for industry – QIAGEN achieved targets

* excluding acquisition, restructuring, integration and related charges

Financials


1 excluding the synthetic DNA business unit, sold in Q2 20042 excluding acquisition, restructuring, integration and related charges as well as amortization o acquired IP

Strong earnings engineStrong earnings engine

18%0.390.46EPS in US$ per share2

24%0.330.41EPS in US$ per share

18%58.569.2Net income2

28%48.762.2Net income

15%24%26%Operating margin2

13%22%24%Operating margin

11%360.3Net sales1

5%380.6398.4Net sales

GrowthFiscal 2004Fiscal 2005In US$ millions unless indicated

QIAGEN Fiscal 2005Financials


Asia9% of revenues RoW

2% of revenues

North America46% of revenues

Europe 43% of revenues

Fiscal 2005 Revenue Distribution

Consumables88% of revenues

Instruments10% of revenues

Other2% of revenues

Financials


Operating income and net income protected by natural hedgeOperating income and net income protected by natural hedge

-10.1408.5398.4Total

-1.276.174.9Revenues other currencies

-3.037.7 34.7Revenues in JPY

-5.9127.7121.8Revenues in Euro

167.0167.0Revenues in US$

Change due to currencyGuidance ratesReportedIn US$ million

Currency Impact Actual to Guidance

Actual

Financials

2.5% foreign currency impact on revenues using Feb 15, 2005 guidance exchange rates


* excluding acquisition, restructuring, integration and related charges as well as amortization of acquired IP

Further Room For ImprovementQIAGEN Margin Development

67%

24%

15%

69%

26%

17%

Gross margin Operating incomemargin*

Net income margin*

2004

2005

Financials


Free cash flow computed using cash from operations less capital expendituresCash EPS computed using cash from operations divided by number of fully diluted shares

Operating cash flow plus 70%Operating cash flow plus 70%

0.360.61Cash EPS in US$ per share

41.077.5Free cash flow

12.613.7Capital expenditures

53.691.2Operating cash flow

-18.104.0Working Capital & others

23.025.0Depreciation & amortization

48.762.2Net income

FY 2004FY 2005In US$ millions unless indicated

QIAGEN Cash Flow StatementFinancials


2006 Guidance

Financials


Summary Revenue Statement 2004 – 2006

~ 10%9%406-418376346Organic growth

~ 12%5%439-451398381Reported revenues/Guidance

~ -2%-9FX impact1

~14%5%448-460398381Revenues FX rate 2005

-33-22-35Acquisitions/Divestments2

2006E2004Growth

05/06Growth04/05

2005In million US$

1 FX rate 2005 / FX rate 01/31/06 2 Revenues from the synthetic DNA business unit, sold in Q2 2004 and the divestment of pAlliance

as well as shifted revenues from PAXgene to BD announced in August, 2005

Financials


~18%26 – 28%26%Operating margin*

~16%0.52 – 0.550.46EPS in US$ per share*

~ 12%439 - 451398Revenues (MUS$)

Growth %2006E2005

Summary Income Statement 2005 – 2006

* excluding acquisition, integration and restructuring related charges as well asamortization of acquired IP and equity-based compensation

2006E Based on FX 01/31/06

Financials


2005

Solid financial performance

Continued as dominant player in pre-analytics

Capitalized on strong growth in core business

Eight transactions for catalytic growth

Gained strong strategic momentum to shape molecular diagnostics markets

Expanded market penetration in Asia

2006

Strong growth in molecular diagnostics

Expand industry standard setter position

Leverage operational strength to further improve margins

Developing – Acquiring – Partnering

2005 Review and 2006 OutlookFinancials


Revenues: 2005: $ 398 million 96–05 CAGR: 25%Net income: 2005: $ 69 million 96–05 CAGR: 33%1

EPS: 2005: $ 0.46 96–05 CAGR: 31%1

Product Range: > 500 consumable products

Instrumentation

Molecular diagnostics and research test kits

IP (12/05): 409 issued patents, 321 pending patentsOver 500 patents under license

Customers: >400,000 customers in Academia,Industrial (Pharma/Biotech) and Diagnostics

Employees: >1.700 employees based in 19 subsidiaries

QIAGEN at a Glance

1 excluding acquisition, restructuring and related charges as well as amortization on acquired IP

Financials


As the innovative market and technology leader, QIAGEN creates indispensable solutions that set standards in enabling access to content from any biological sample.

Our mission is to enable our customers to achieve outstanding success and breakthroughs in research, applied markets, drug development and molecular diagnostics. We thereby make improvements in life possible.

Our commitment to the markets we serve drives our innovation and leadership in all areas where solutions such as sample collection, stabilization, separation, purification, storage, handling and processing are required.

The exceptional talent, skill and passion of our employees are key to QIAGEN’s excellence, success and value.

We create indispensable solutions that enable access to content from any biological sample

forward looking statements · the following slides may contain certain summary information about...

Documents